

GRIFOLS

Grifols launches new vial sizes of PROLASTIN, the alpha₁ antitrypsin (AAT) augmentation therapy most prescribed worldwide

- *Now available in 4- and 5-gram options, the new PROLASTIN vials enable healthcare professionals to meet more easily the dosing needs of patients living with severe alpha₁-antitrypsin deficiency, also known as alpha-1*
- *With more than 35 years of clinical experience, Grifols' PROLASTIN brand¹ is the most prescribed treatment of alpha-1, a debilitating lung disease*
- *The new vial sizes will be available in Germany and Denmark in February, with rollout to additional European markets throughout 2024*

Barcelona, Spain, Feb. 5, 2024 – Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced it has introduced 4- and 5-gram vials of PROLASTIN (alpha₁-proteinase inhibitor [human]) used for long-term alpha₁ antitrypsin (AAT) augmentation therapy in patients with severe alpha₁-antitrypsin deficiency (alpha-1) who show evidence of progressive lung disease.

Alpha-1 is an underdiagnosed² genetic disorder that occurs when a patient has low levels of AAT, a protective protein that safeguards the lungs. With an excellent safety record³, PROLASTIN augments patients' levels of the AAT protein through intravenous administration, making the alpha₁-proteinase inhibitor dose immediately available in the patient's bloodstream.

Strengthening Grifols' PROLASTIN brand portfolio, the new 4- and 5-gram vials will enable healthcare professionals to meet the dosing needs of patients more easily, all while using less packaging waste throughout the process and reducing storage space. The currently approved dosage of PROLASTIN is 60 mg/kg in weekly infusions. Previously the vials were only available in a 1-gram dose.

“For over 35 years, PROLASTIN has always been trusted by health care professionals. The new vial options will better enable healthcare professionals to tailor treatment and enhance the patient experience,” said Joana Sabat, SVP Biopharma Launch Unit. “Grifols continues to build

¹ Includes Prolastin®, Prolastina®, Prolastin®-C and Prolastin®-C Liquid.

² American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med.* 2003;168(7):818-900. doi:10.1164/rccm.168.7.818.

³ STOCKS, J. M. et al. Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. *BMC clinical pharmacology*, [s. l.], v. 10, p. 13, 2010.

GRIFOLS

on its strong commitment to the alpha-1 community through new solutions that make the management of alpha-1 easier.”

The PROLASTIN® 4- and 5-gram vials will be available in Germany and Denmark in February, before being rolled out to other European markets during 2024.

About alpha₁-antitrypsin deficiency (alpha-1)

Alpha-1 is a rare hereditary disease defined by a deficiency or absence of the alpha₁ antitrypsin protein in plasma. It is the most common cause of severe pulmonary emphysema and chronic obstructive pulmonary disease (COPD) in adults, as well as the most common cause of liver disease in children.

This illness is more prevalent than other rare lung diseases such as cystic fibrosis and pulmonary arterial hypertension. Alpha-1 symptoms vary depending on the degree of severity and type of genetic mutation, as well as external factors.

Alpha-1 affects some 3.4 million people around the world. Ninety percent of individuals remain undiagnosed with severe alpha-1, even though a simple screening test will quickly detect the condition.

For more information about alpha-1, please visit: www.alpha1.org.

About PROLASTIN

PROLASTIN is indicated for long-term augmentation therapy in patients with severe alpha₁-proteinase inhibitor deficiency (phenotypes PiZZ, PiZ [null], Pi [null,null] and PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV₁) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha₁-proteinase inhibitor deficiency.⁴

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

⁴ Grifols. PROLASTIN® Summary of Product Characteristics. Accessed February 2024.

GRIFOLS

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com.

MEDIA CONTACT:

Media Press Office

media@grifols.com

Tel. +34 93 571 00 02

INVESTORS:

Investors Relations Department & Sustainability

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group